{"doi":"10.3390/microorganisms11020277","title":"Could the Microbiota Be a Predictive Factor for the Clinical Response to Probiotic Supplementation in IBS-D? A Cohort Study","abstract":"<jats:p>Background: Increasing evidence suggests the beneficial effects of probiotics in irritable bowel syndrome (IBS), but little is known about how they can impact the gut microbiota. Our objective was to evaluate the effects of a multistrain probiotic on IBS symptoms, gut permeability and gut microbiota in patients with diarrhoea-predominant IBS (IBS-D). Methods: Adults with IBS-D were enrolled in an open-label trial to receive a multistrain probiotic for 4 weeks. Abdominal pain, stool frequency, quality of life, gut permeability, and the luminal and adherent microbiota from colonic biopsies were evaluated before and after supplementation. Results: Probiotics significantly improved symptoms and quality of life, despite having no impact on permeability in the global population. In the population stratified by the response, the diarrhoea responders displayed reduced colonic permeability after supplementation. The luminal and adherent microbiota were specifically altered depending on the patients’ clinical responses regarding pain and diarrhoea. Interestingly, we identified a microbial signature in IBS-D patients that could predict a response or lack of response to supplementation. Conclusions: The multistrain probiotic improved the symptoms of IBS-D patients and induced distinct effects on the gut microbiota according to the patient’s clinical response and initial microbiota composition. Our study further supports the need to develop individualised probiotic-based approaches regarding IBS.</jats:p>","journal":"Microorganisms","year":2023,"id":631408,"datarank":0.3453877639491069,"base_score":2.302585092994046,"endowment":2.302585092994046,"self_citation_contribution":0.3453877639491069,"citation_network_contribution":0.0,"self_endowment_contribution":0.3453877639491069,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":9,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":690740,"name":"Lucille Quénéhervé","orcid":"0000-0001-5443-2579","position":1,"is_corresponding":false},{"id":1636278,"name":"Philippe Bordron","orcid":null,"position":2,"is_corresponding":false},{"id":1636279,"name":"Philippe Aubert","orcid":null,"position":3,"is_corresponding":false},{"id":1636280,"name":"Tony Durand","orcid":null,"position":4,"is_corresponding":false},{"id":1277892,"name":"Thibauld Oullier","orcid":null,"position":5,"is_corresponding":false},{"id":1636281,"name":"Claude Blondeau","orcid":null,"position":6,"is_corresponding":false},{"id":1636283,"name":"Samira Ait Abdellah","orcid":"0000-0001-8649-4598","position":7,"is_corresponding":false},{"id":1636285,"name":"Stanislas Bruley des Varannes","orcid":null,"position":8,"is_corresponding":false},{"id":773950,"name":"Samuel Chaffron","orcid":"0000-0001-5903-617X","position":9,"is_corresponding":false},{"id":1192754,"name":"Emmanuel Coron","orcid":"0000-0003-2431-7670","position":10,"is_corresponding":false},{"id":701115,"name":"Michel Neunlist","orcid":"0000-0003-1892-5071","position":11,"is_corresponding":false},{"id":1636277,"name":"Justine Marchix","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Could the Microbiota Be a Predictive Factor for the Clinical Response to Probiotic Supplementation in IBS-D? A Cohort Study","abstract":"<jats:p>Background: Increasing evidence suggests the beneficial effects of probiotics in irritable bowel syndrome (IBS), but little is known about how they can impact the gut microbiota. Our objective was to evaluate the effects of a multistrain probiotic on IBS symptoms, gut permeability and gut microbiota in patients with diarrhoea-predominant IBS (IBS-D). Methods: Adults with IBS-D were enrolled in an open-label trial to receive a multistrain probiotic for 4 weeks. Abdominal pain, stool frequency, quality of life, gut permeability, and the luminal and adherent microbiota from colonic biopsies were evaluated before and after supplementation. Results: Probiotics significantly improved symptoms and quality of life, despite having no impact on permeability in the global population. In the population stratified by the response, the diarrhoea responders displayed reduced colonic permeability after supplementation. The luminal and adherent microbiota were specifically altered depending on the patients’ clinical responses regarding pain and diarrhoea. Interestingly, we identified a microbial signature in IBS-D patients that could predict a response or lack of response to supplementation. Conclusions: The multistrain probiotic improved the symptoms of IBS-D patients and induced distinct effects on the gut microbiota according to the patient’s clinical response and initial microbiota composition. Our study further supports the need to develop individualised probiotic-based approaches regarding IBS.</jats:p>","is_dataset_classified":null,"base_score":2.302585092994046,"endowment":2.302585092994046,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36838241","pmcid":"PMC9964083","openalex_id":"https://openalex.org/W4318043413","authors":[],"funders":[{"funder_name":"PiLeJe Laboratoire and supported in part by the Région Pays de la Loire (MibioGate)","grant_id":"ANR-19-CE14-0024","title":"The microbiome-gut-brain axis in Autism Spectrum Disorder"},{"funder_name":"PiLeJe Laboratoire","grant_id":"no","title":null}],"total_grants":2,"fwci":1.8273,"citation_percentile":0.8383558,"influential_citations":0,"citation_trend":[{"year":2023,"count":1},{"year":2024,"count":6},{"year":2025,"count":2}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/2076-2607/11/2/277/pdf?version=1674956419","host_type":"journal"},{"url":"https://www.mdpi.com/2076-2607/11/2/277/pdf?version=1674956419","host_type":"publisher"},{"url":"https://www.mdpi.com/2076-2607/11/2/277/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/microorganisms11020277","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/36838241","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9964083","host_type":"repository"},{"url":"https://nantes-universite.hal.science/hal-04163623","host_type":"repository"},{"url":"https://doaj.org/article/7b1196c7d10a4aed924b010df276d385","host_type":"repository"},{"url":"https://dx.doi.org/10.3390/microorganisms11020277","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9964083/pdf/microorganisms-11-00277.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC9964083","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC9964083?pdf=render","host_type":"Europe_PMC"},{"url":"http://dx.doi.org/10.3390/microorganisms11020277","host_type":""},{"url":"https://nantes-universite.hal.science/hal-04163623v1","host_type":""},{"url":"https://nantes-universite.hal.science/hal-04163623v1/document","host_type":""},{"url":"https://doi.org/https://doi.org/10.3390/microorganisms11020277","host_type":""}],"fields_of_study":["Gastrointestinal motility and disorders","Gut microbiota and health","Probiotics and Fermented Foods","0301 basic medicine","0303 health sciences","03 medical and health sciences"],"mesh_terms":[],"keywords":["Probiotic","Cohort","Medicine","Gut flora","Cohort study","Internal medicine","Immunology","Biology","Bacteria","Genetics","Probiotics","Microbiota","Diarrhoea","irritable bowel syndrome","Intestinal Permeability","QH301-705.5","[SDV]Life Sciences [q-bio]","610","Article","[SDV] Life Sciences [q-bio]","Biology (General)"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-05T23:32:38.064877Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}